New treatment for neuropathic pain using a CBD analogue
Development of KLS-13019 for Neuropathic Pain
This study is testing a new medicine called KLS-13019 to see if it can help relieve nerve pain caused by chemotherapy, aiming to offer a safer and better option for people dealing with this tough side effect.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kannalife Sciences, INC. NIH-funded |
| Lab location | 1 site (Lloyd Harbor, UNITED STATES) |
| Project ID | NIH-10704175 on NIH RePORTER |
What this research studies
This research focuses on developing KLS-13019, a new analogue of cannabidiol (CBD), to treat neuropathic pain, particularly chemotherapy-induced peripheral neuropathy (CIPN). The study investigates how KLS-13019 can prevent and alleviate pain sensitivity caused by chemotherapy drugs like paclitaxel. Using a mouse model, researchers have shown that KLS-13019 is more effective than traditional opioids in reducing pain sensitivity after it has developed. The goal is to provide a safer and more effective oral treatment option for patients suffering from this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients experiencing neuropathic pain, particularly those with chemotherapy-induced peripheral neuropathy.
Not a fit: Patients who do not have neuropathic pain or those whose pain is not related to chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective oral treatment for patients suffering from neuropathic pain, reducing reliance on opioids.
How similar studies have performed: Previous studies have shown success with CBD in managing neuropathic pain, making this approach promising yet still innovative with the new analogue.
Where this research is happening
Lloyd Harbor, UNITED STATES
- Kannalife Sciences, INC. — Lloyd Harbor, United States (Active)
Researchers
- Principal investigator: Brenneman, Douglas Eric — Kannalife Sciences, INC.
- Study coordinator: Brenneman, Douglas Eric
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.